| Literature DB >> 19234888 |
Esa Jämsen1, Ioannis Stogiannidis, Antti Malmivaara, Jorma Pajamäki, Timo Puolakka, Yrjö T Konttinen.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2009 PMID: 19234888 PMCID: PMC2823239 DOI: 10.1080/17453670902805064
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
The inclusion criteria for original papers
| The report concerns the results of management of infected knee arthroplasty only with one-stage or two-stage exchange arthroplasty. |
| The study can be classified into one of the following groups: |
| – randomized controlled trial |
| – prospective study comparing two simultaneous treatment groups |
| – prospective study with historical controls |
| – prospective case series with no comparison group |
| – retrospective study comparing two simultaneous treatment groups |
| – retrospective study with historical control group |
| – retrospective study with no control group |
| Study includes more than 5 cases treated. |
| The paper is written in English or it has an abstract in English. |
| One or more of the following outcome variables is reported: |
| – number of all infections appearing after the treatment |
| – number of reinfections |
| – clinical status at follow-up, reported using Hospital for Special Surgery or Knee Society knee score |
| – range of motion at follow-up |
Original studies included: materials and outcome
| Study | Materials | Outcome | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | H | I | ||
| Rosenberg et al. | 1988 | 26 | 1981–1986 | 65/31/4 | 67 | 2-stage, no spacer | 29 (12–57) | 100 | 78 | NA |
| Booth and Lotke a | 1989 | 25 | 1984–1988 | NA | 67 | 2-stage, PMMA block | 25 (6–59) | 96 | 82 | 100 |
| Henderson and Booth a | 1991 | 28 | 1984–1989 | 89/11/0 | 73 | 2-stage, PMMA block | 27 (12–79) | 97 | 86 | 90 |
| von Foersteret et al. c | 1991 | 104 | 1976–1985 | 61/29/10 | NA | 1-stage | 76 (60–180) | 73 | NA | NA |
| Göksan and Freeman | 1992 | 18 | 1979–1989 | 39/56/5 | 61 | 1-stage | 60 (12–120) | 94 | NA | 85 |
| Masri et al. | 1994 | 24 | 1987–1993 | 75/8/17 | 66 | 2-stage, PROSTALAC | 26 (6–73) | 96 | 80 | 86 |
| Whiteside | 1994 | 33 | NA | 85/15/0 | NA | 2-stage, PMMA block | 24 | 97 | NA | 98 |
| Gusso et al. | 1995 | 5 | NA | 80/NA/NA | NA | 2-stage, PMMA block | (4–18) | 100 | 78 | 105 |
| Goldman et al. | 1996 | 64 | 1977–1993 | 70/25/5 | 67 | 2-stage, no spacer b | 90 (24–204) | 97 | 78 | 94 |
| Gacon et al. c | 1997 | 29 | 1984–1994 | 97/3/0 | 70 | 2-stage, PMMA block | 42 | 83 | 80 | 95 |
| Lu et al. c | 1997 | 8 | NA | NA | NA | 1-stage | 20 | 100 | NA | NA |
| McPherson et al. | 1997 | 21 | 1993–1996 | NA | 64 | 2-stage, no spacer | 17 (5–33) | 95 | 77 | 99 |
| Hirakawa et al. | 1998 | 55 | 1980–1993 | 75/25/0 | 67 | 2-stage, PMMA block | NA | 82 | 79 | 83 |
| Lecuire et al. c | 1999 | 12 | 1989–1998 | NA | NA | 2-stage, no spacer | 12 | 100 | NA | 96 |
| Fehring et al. | 2000 | 25 | 1986–1995 | NA | 68 | 2-stage, PMMA block | 36 (24–72) | 88 | 83 | 98 |
| 15 | 1996–1999 | NA | NA | 2-stage, artic. PMMA | 27 (24–36) | 93 | 84 | 105 | ||
| Haddad et al. | 2000 | 45 | 1987–1996 | 80/13/7 | 69 | 2-stage, PROSTALAC | 48 (20–112) | 98 | 72 | 95 |
| Kirschner et al. c | 2000 | 6 | 1996–1997 | NA | 62 | 2-stage, artic. PMMA | 19 (13–21) | 100 | NA | NA |
| Mont et al. | 2000 | 69 | 1989–1993 | NA | 66 | 2-stage, PMMA block | 63 (36–114) | 93 | 86 | 96 |
| Lonner et al. | 2001 | 53 | 1983–1997 | NA | NA | 2-stage, PMMA block | 56 (24–144) | 91 | NA | NA |
| Emerson et al. | 2002 | 26 | 1986–1994 | NA | 66 | 2-stage, PMMA block | 90 (34–152) | 92 | NA | 94 |
| 22 | 1995–1999 | NA | 65 | 2-stage, RPS | 46 (31–77) | 100 | NA | 108 | ||
| Siebel et al. | 2002 | 10 | NA | NA | 66 | 2-stage, artic. PMMA | 18 (6–26) | 100 | 64 | 87 |
| Jhao and Jiang | 2003 | 7 | 1994–2001 | 86/14/0 | 68 | 2-stage, no spacer | 42 (12–84) | 100 | 86 | 91 |
| Pietsch et al. c | 2003 | 24 | 1999–2002 | NA | d | 2-stage, RPS | 15 (5–33) | 96 | NA | NA |
| Haleem et al. | 2004 | 96 | 1989–1994 | 77/15/8 | 69 | 2-stage, PMMA block | 86 (30–158) | 96 | 50 | 90 |
| Buechel et al. | 2004 | 22 | 1981–1993 | 95/5/0 | 71 | 1-stage | 122 (17–235) | 100 | 80 | NA |
| Durbhakula et al. | 2004 | 24 | 1998–2001 | NA | 72 | 2-stage, artic. PMMA | 33 (28–51) | 100 | 82 | 104 |
| Meek et al. | 2004 | 54 | 1997–1999 | NA | NA | 2-stage, PROSTALAC | 41 | 96 | 76 | 87 |
| Cuckler | 2005 | 44 | 1994–2002 | NA | 68 | 2-stage, RPS | 65 (24–120) | 100 | 84 | 112 |
| Hofmann et al. | 2005 | 50 | 1989–2001 | NA | 67 | 2-stage, RPS | 74 (24–150) | 94 | 89 | 4–104 |
| MacAvoy and Ries | 2005 | 13 | NA | NA | 58 | 2-stage, B&S | 28 (15–44) | 100 | NA | 98 |
| Pitto et al. | 2005 | 21 | 2000–2003 | NA | 67 | 2-stage, artic. PMMA | 24 (12–43) | 100 | 81 | 94 |
OA: osteoarthritis; RA: rheumatoid arthritis; ROM: range of motion; NA: not available; PMMA: polymethylmethacrylate bone cement; PROSTALAC: prosthesis of antibiotic-loaded cement; RPS: resterilized prosthesis spacer; B&S: ball-and-socket spacer;
a partly overlapping data;
b includes 7 knees with PMMA block,
c non-English publications.
d range 42–78
A No. of knees
B Year(s) of collection
C Diagnosis OA/RA/other, %
D Average age at operation, years
E Revision type, spacer
F Length of follow-up, months (range)
G Rate of eradication of infection, %
H Average clinical knee score postoperatively
I ROM or flexion postoperatively, degrees
Quality scores of the 25 studies published in English that were included. Values are number of studies
| Quality measure | Measure reported | Measure not reported |
|---|---|---|
| Materials | ||
| Average age | 21 | 4 |
| Male-to-female ratio | 23 | 2 |
| Primary diagnoses | 13 | 12 |
| ASA or other risk classification | 2 | 23 |
| Pathogens | 23 | 2 |
| Preoperative clinical knee score | 9 | 16 |
| Preoperative range of motion or flexion range | 9 | 16 |
| Intervention | ||
| Peroperative antibiotic treatment | 19 | 6 |
| Type of spacer | 22 | 1 |
| Mean time between the two stages | 16 | 7 |
| Postoperative antibiotic treatment | 9 | 16 |
| Rehabilitation | 6 | 19 |
| Results | ||
| No. of all new infections | 25 | 0 |
| No. of reinfections/recurrent infections | 24 | 1 |
| No. of other failures | 11 | 14 |
| Postoperative clinical knee score | 20 | 5 |
| Postoperative range of motion/flexion | 23 | 2 |
| True | False | |
| Methodology | ||
| Were both advantages and disadvantages of the treatment described? | 8 | 17 |
| Was the number of patients excluded less than 20% of the number of patients included? | 21 | 4 |
| Was the species of pathogen idenepsied used as an exclusion criterion? | 3 | 22 |
| Was loss to follow-up less than 20%? | 25 | 0 |
Figure 1.Rates of recurrent and new infections. Studies sorted by length of follow-up.
Figure 2.Rates of recurrent and new infections after revision arthroplasty for infection. Series sorted by publication year.
Figure 3.The effect of treatment approach on the average postoperative range of motion or maximal flexion. Each dot represents one study.
Overview of studies published after the literature search
| A | B | C | D | E | F | G | H | I | |
|---|---|---|---|---|---|---|---|---|---|
| Hart and Jones | 2006 | 48 | 1998–2003 | articulating PMMA | 49 (26–85) | 88 | NA | c | |
| Huang et al. | 2006 | 21 | 1996–2002 | RPS | 52 (30–102) | 95 | 85 | 81 a | |
| Jämsen et al. | 2006 | 34 | 1993–2003 | RPS (n = 24) | 25 (2–68) | 91 | 104 | 82 a | |
| static PMMA (n = 10) | 49 (2–86) | 75 | 92 | 79 a | |||||
| Trezies et al. | 2006 | 11 | 1992–2004 | new femoral component + polyethylene tibial insert | 65 | 91 | NA | ||
| Hsu et al. | 2007 | 28 | 1996–2004 | static PMMA (n = 7) | 101 (63–120) | 86 | 78 | 81 a | |
| articulating PMMA (n = 21) | 58 (27–96) | 91 | 95 | 89 a | |||||
| Mittal et al. | 2007 | 37 | 1987–2003 | articulating or static PMMA | 51 (24–111) | 75 | NA | d | |
| Abstracts | |||||||||
| Pietsch et al. | 2006 | 33 | 2000–2003 | RPS | 28 (12–48) | 91 | 87 b | e | |
| Souillac et al. | 2006 | 28 | 2000–2003 | articulating PMMA | (20–48) | 86 | NA |
NA: not available; PMMA: polymethylmethacrylate bone cement; RPS: resterilized prosthesis spacer
A Study
B No. of knees
C Year(s) of collection
D Spacer
E Follow-up, months (range)
F Infection eradication rate, %
G Range of motion, degrees
H Clinical outcome
a Knee Society score
b Hospital for Special Surgery knee score
I Note
c short-term antibiotic therapy
d resistant organisms: methicillin-resistant Staphylococcus aureus/epidermidis
e prospective study
| Literature databases reviewed: |
| Medline 1966 to present (via Ovid), Medline Daily Update (via Ovid), Medline In-Process and Other Non-indexed Citations (via Ovid), CINAHL (via Ovid), British Nursing Index (via Ovid), Cochrane Central Register of Controlled Trials (via Ovid), Cochrane Database of Systematic Reviews (via Ovid), Database of Abstracts of Reviews of Effects (via Ovid), ACP Journal Club (via Ovid), NHS Health Technology Assessment (via CRD), NHS Economic Evaluation Database (via CRD). |
| Search strategy for Medline and CINAHL: |
| 1) arthroplasty, replacement, knee/ |
| 2) knee prosthesis/ |
| 3) “knee prosthes$”.mp |
| 4) “knee arthroplast$”.mp |
| 5) “knee replacement?”.mp |
| 6) reoperation/ |
| 7) “revis$”.mp |
| 8) “reimplant$”.mp |
| 9) “exchang$”.mp |
| 10) prosthesis-related infections/ |
| 11) infection/ |
| 12) wound infection/ |
| 13) surgical wound infection/ |
| 14) “infect$”.mp |
| 15) (1 or 2 or 3 or 4 or 5) and (6 or 7 or 8 or 9) and (10 or 11 or 12 or 13 or 14) |
| Search strategy for EBM databases: Cochrane Central Register of Controlled Trials, Database or Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, ACP Journal Club (via Ovid): |
| 1) knee replacement?.mp |
| 2) knee arthroplast$.mp |
| 3) knee prosthes$.mp |
| 4) arthroplasty, replacement, knee.mp |
| 5) reoperat$.mp |
| 6) revis$.mp |
| 7) reimplant$.mp |
| 8) exchang$.mp |
| 9) infect$.mp |
| 10) prosthesis-related infection?.mp |
| 11) (1 or 2 or 3 or 4) and (5 or 6 or 7 or 8) and (9 or 10) |
| Search strategy for Science Citation Index: |
| 1) TS=arthroplasty |
| 2) TS=infection |
| 3) TS=knee |
| 4) TS=(revision OR reoperation OR reimplantation OR exchange) |
| 5) #1 AND #2 AND #3 AND #4 |
| Search strategy for Health Technology Assessment, NHS Economic Evaluation Database: |
| 1) prosthesis-related infections (subject headings) |
| 2) arthroplasty-replacement-knee (subject headings) OR knee-prosthesis (subject headings) AND infect (all fields) |
| 3) knee replacem OR knee arthroplas AND infect |
| STUDY QUALITY Question: Yes; No; Unclear |
| Was the patient population described in sufficient detail so that you could compare it to the patient population you treat or to the materials of other studies on the same subject? |
| – Average age |
| – Male-to-female ratio |
| – Indications for primary knee replacement |
| – ASA classification |
| – Pathogens idenepsied |
| – Preoperative Knee Society (KSS) or Hospital for Special Surgery (HSS) knee score |
| – Preoperative range of motion |
| Was the intervention described in sufficient detail so that you could provide the same treatment for your own patiens? |
| – Use of antibiotics peroperatively |
| – The type of spacer used in two-stage revisions |
| – The length of interim period between the stages in two-stage revisions |
| Was the associated treatment/rehabilitation described in sufficient detail so that you could provide the same for your own patients? |
| – Use of antibiotics postoperatively |
| – Rehabilitation |
| Were the primary outcome variables reported? |
| – Number of all post-treatment infections |
| – Number of reinfections |
| – Postoperative KSS or HSS |
| – Postoperative range of motion |
| Were both advantages and disadvantages of the treatment presented? |
| Was the proportion of patients excluded less than 20% of the number of patients included? |
| Was the species of infecting pathogen used as exclusion criterion? |
| Was loss to follow-up less than 20%? |